Aikuisten fibromyalgian monisäikeinen hoito
Permalink
Citation
Leino-Arjas , P & Markkula , R 2020 , ' Aikuisten fibromyalgian monisäikeinen hoito ' , Duodecim , Vuosikerta. 136 , Nro 8 , Sivut 871-877 . < https://www.terveysportti.fi/xmedia/duo/duo15519.pdf >
| Title: | Aikuisten fibromyalgian monisäikeinen hoito |
| Author: | Leino-Arjas, Päivi; Markkula, Ritva |
| Contributor organization: | HUS Leikkaussalit, teho- ja kivunhoito Helsingin yliopisto Diagnostis-terapeuttinen osasto HUS Helsingin ja Uudenmaan sairaanhoitopiiri |
| Date: | 2020 |
| Language: | fin |
| Number of pages: | 7 |
| Belongs to series: | Duodecim |
| ISSN: | 0012-7183 |
| URI: | http://hdl.handle.net/10138/331975 |
| Abstract: | Fibromyalgiapotilaan hoito on usein vaativaa, ja siinä onnistuminen vaatii hyvää, pitkäjänteistä yhteistyötä potilaan kanssa. Uutta tietoa sekä lääkehoidon että lääkkeettömien hoitomuotojen vaikuttavuudesta on kertynyt viime vuosina runsaasti, ja uusia näyttöön perustuvia hoitosuosituksia on julkaistu. Myös potilasnäkökulmaa on hiljattain kartoitettu. Niin suositukset kuin usein potilaatkin asettavat lääkkeettömät vaihtoehdot ensisijaisiksi. Lääkehoitoa voidaan käyttää niiden tukena. Yleisperiaatteet fibromyalgian hoidossa ovat pitkälti yhtenevät muun hyvänlaatuisen pitkäaikaisen kivun hoidon kanssa. Tärkeää hoitosuhteessa on tiedon jakaminen fibromyalgiasta potilaan oman pystyvyyden tunteen ja muutosjoustavuuden tukemiseksi. |
| Description: | Vertaisarvioitu. English summary |
| Subject: |
Acupuncture Therapy
Analgesics Cognitive Behavioral Therapy Combined Modality Therapy Exercise Therapy Fibromyalgia +drug therapy +epidemiology +therapy Mindfulness 3121 Yleislääketiede, sisätaudit ja muut kliiniset lääketieteet 317 Farmasia |
| Peer reviewed: | Yes |
| Usage restriction: | openAccess |
| Self-archived version: | publishedVersion |
Files in this item
Total number of downloads: Loading...
| Files | Size | Format | View |
|---|---|---|---|
| duo15519.pdf | 287.5Kb |
View/ |
This item appears in the following Collection(s)
-
Articles from TUHAT system
[53268]
Related items
Showing items related by title, author, creator and subject.
-
(2018)Releasing the patient's immune system against their own malignancy by the use of checkpoint inhibitors is delivering promising results. However, only a subset of patients currently benefit from them. One major limitation of these therapies relates to the inability of T cells to detect or penetrate into the tumor resulting in unresponsiveness to checkpoint inhibition. Virotherapy is an attractive tool for enabling checkpoint inhibitors as viruses are naturally recognized by innate defense elements which draws the attention of the immune system. Besides their intrinsic immune stimulating properties, the adenoviruses used here are armed to express tumor necrosis factor alpha (TNFa) and interleukin-2 (IL-2). These cytokines result in immunological danger signaling and multiple appealing T-cell effects, including trafficking, activation and propagation. When these viruses were injected into B16.OVA melanoma tumors in animals concomitantly receiving programmed cell-death protein 1 (PD-1) blocking antibodies both tumor growth control (p <0.0001) and overall survival (p <0.01) were improved. In this set-up, the addition of adoptive cell therapy with OT-I lymphocytes did not increase efficacy further. When virus injections were initiated before antibody treatment in a prime-boost approach, 100% of tumors regressed completely and all mice survived. Viral expression of IL2 and TNFa altered the cytokine balance in the tumor microenvironment towards Th1 and increased the intratumoral proportion of CD8+ and conventional CD4+ T cells. These preclinical studies provide the rationale and schedule for a clinical trial where oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) is used in melanoma patients receiving an anti-PD-1 antibody.
-
(2021)Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies.